Express significantly improves the symptoms of Parkinson's disease patients, and the phase 2 clinical results of the new mechanism therapy are positive

▎WuXi AppTec Content Team Editors Today, Cerevance announced that its potential "first-in-class" oral Parkinson's disease treatment CVN424 has achieved positive results in a Phase 2 clinical trial
.

In addition to meeting safety targets, CVN424 provided a statistically significant and clinically meaningful dose-dependent improvement in the "OFF" period of patients
.

The "OFF" period refers to the period of time during which a patient experiences symptoms of Parkinson's disease even after receiving treatment
.

Cerevance's drug discovery platform is based on a new technology called NETSseq, which can label and collect specific disease-related cell types from patient brain tissue, and then perform transcriptome and epigenetic analysis on them to discover New targets for the treatment of central nervous system diseases
.

CVN424 is an innovative therapy based on the discovery of this platform that selectively targets the dopamine D2 receptor-dependent indirect signaling pathway associated with Parkinson's disease, aiming to produce the same positive effects as levodopa or deep brain stimulation, while Avoid adverse reactions
.

▲ NETSseq technology platform (Image source: Cerevance's official website) In this randomized, double-blind, placebo-controlled Phase 2 clinical trial, about 135 Parkinson's disease patients received two different doses of CVN424
.

They received stable treatment with levodopa or other Parkinson's disease drugs, but still had an "OFF" period of at least two hours a day
.

Trial results showed that after 4 weeks of treatment, high-dose CVN424 improved the "OFF" period by 1.
3 hours compared with placebo (p=0.
042)
.

At the same time, the "ON" time without dyskinesia increases
.

Unlike other adjuvant therapies co-administered with levodopa, CVN424 decreased daytime sleepiness indicators in patients compared with placebo
.

"We are delighted to report these results, which we believe demonstrate that CVN424 can provide significant improvement in patients without exacerbating the side effects of dopamine medications ," said Brad Margus, CEO of Cerevance
.

"We look forward to rapidly advancing CVN424 into multiple large clinical trials.
study, targeting regulatory approval
.

" Reference: [1] Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson's Disease Drug Working Through a New Mechanism.
Retrieved March 31, 2022, from https:// .
com/news-release/2022/03/31/2414037/0/en/Cerevance-Reports-Positive-Phase-2-Clinical-Trial-Results-with-CVN424-a-Parkinson-s-Disease-Drug-Working -Through-a-New-Mechanism.
htmlDisclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.